The treatment using the combinations of IFN-α and inhibitors (TPL2i, PD98059 or roflumilast) exhibited a stronger inhibitory effect on the viability of bladder cancer cells than the individual IFN-α treatment (Fig. 3f and Additional file 6: Figure S6A-B). This evidence concerns the gene IFNA2 and urinary bladder cancer.